This fixed combination drug is not indicated for initial therapy of hypertension. Hypertension requires therapy titrated to the individual patient. If the fixed combination represents the dosage so determined, its use may be more convenient in patient management. The treatment of hypertension is not static, but must be re-evaluated as conditions in each patient warrant.
ALDORIL (Methyldopa-Hydrochlorothiazide) combines two antihypertensives: methyldopa and hydrochlorothiazide.
ALDORIL is indicated for the treatment of hypertension.
Media Articles Related to Aldoril (Methyldopa / Chlorothiazide)
CHMP Backs Selexipag for Pulmonary Arterial Hypertension
Source: Medscape Family Medicine Headlines [2016.01.29]
Selective prostaglandin receptor agonist has mechanism distinct from prostacyclin and its analogs.
Actelion receives Health Canada approval for Uptravi (selexipag) for the long-term treatment of pulmonary arterial hypertension
Source: Cardiovascular / Cardiology News From Medical News Today [2016.01.26]
Actelion has announced that Health Canada has granted a Notice of Compliance (NOC) approving the orally active, selective IP prostacyclin receptor agonist Uptravi (selexipag),originally discovered...
The age-related change of angiotensin receptor promotes hypertension
Source: Hypertension News From Medical News Today [2016.01.20]
Heterodimerization of AT1R with P2Y6R along with age promotes angiotensin II-induced hypertension.
Formulation scientists to rescue patients with pulmonary arterial hypertension
Source: Huntingtons Disease News From Medical News Today [2016.01.15]
Overview of a type of high blood pressure of the arteries of the lungs and the heart and a new patient-friendly inhalation treatment.
Actelion announces US commercial availability of UPTRAVI (selexipag) for the treatment of pulmonary arterial hypertension
Source: Hypertension News From Medical News Today [2016.01.05]
Actelion has announced the commercial availability of the oral, selective, IP prostacyclin receptor agonist, UPTRAVI® (selexipag) for the treatment of pulmonary arterial hypertension (PAH) in...
Published Studies Related to Aldoril (Methyldopa / Chlorothiazide)
Combination of a thiazide, a vasodilator and reserpine compared with methyldopa plus hydrochlorothiazide in the treatment of hypertension in Zimbabwe. [1990.03.03]
Brinerdin (Sandoz), a combination of a diuretic (clopamide 5 mg), a vasodilator (dihydro-ergocristine 0.5 mg) and reserpine (0.1 mg) (CDR) was compared with methyldopa (MD) plus hydrochlorothiazide (HCT) for antihypertensive effect, adverse reactions, compliance and patient preference in an open cross-over trial...
Evaluation of the efficacy and safety of enalapril plus hydrochlorothiazide plus methyldopa vs standard triple therapy in the treatment of moderate to severe hypertension: results from a multicentre study. [1990.02]
We report the results of a randomized, double-blind, parallel group multicentre study in 120 patients with moderate to severe hypertension, comparing two different types of antihypertensive treatment: a) the standard 'triple therapy' with hydrochlorothiazide, propranolol and hydralazine, and b) the combination of an ACE inhibitor, enalapril with hydrochlorothiazide (HCTZ) and methyldopa...
Oral enalapril-hydrochlorothiazide-methyldopa as first line treatment for severe hypertension in Nigerians. [2004.01]
A combination of low-dose oral enalapril, methyldopa and hydrochlorothiazide was evaluated in the acute treatment of severe hypertension. Blood pressure moved from an average 210/120 mmHg at the onset to an average 135/79 mmHg within 24 hours, without any significant side effects and at about half the cost of commonly used parenteral hydralazine..
Page last updated: 2016-01-29